Effects of a dopamine receptor agonist and atropine sulfate on absorption of valproic acid in rats

Biomedical Research

Volumn 30, Issue 2, 2009, Pages 101-106

  Kameya, Hiromasa ^a   Hokama, Nobuo ^a   Hobara, Norio ^a   Ohshiro, Susumu ^a   Uno, Tsukasa ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; PRAMIPEXOLE; VALPROIC ACID; BENZOTHIAZOLE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAERGIC RECEPTOR AFFECTING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PRAMIPEXOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; GASTROINTESTINAL MOTILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; DRUG EFFECT; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; ROC CURVE; SPRAGUE DAWLEY RAT;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; ATROPINE; BENZOTHIAZOLES; DOPAMINE AGONISTS; GABA AGENTS; GASTROINTESTINAL MOTILITY; INTESTINAL ABSORPTION; MALE; MUSCARINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; ROC CURVE; VALPROIC ACID;

EID: 67649804911     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.30.101     Document Type: Article

References (23)

1. Ben-Menachem E, Schmitz B, Tomson T and Vajda F (2006) Role of valproate across the ages. Treatment of epilepsy in adults. Acta Neurol Scand 114, 14-27.
2. Binkerd PE, Rowland JM, Nau H and Hendrickx AG (1988) Evaluation of valproic acid (VPA) developmental toxicity and pharmacokinetics in Sprague-Dawley rats. Fundam Appl Toxicol 11, 485-493.
3. Brodie BB and Hogben CA (1957) Some physico-chemical factors in drug action. J Pharm Pharmacol 9, 345-380.
4. Ferrari F, Pelloni F and Giuliani D (1993) Behavioural evidence that different neurochemical mechanisms underly stretcbing-yawning and penile erection induced in male rats by SND 919, a new selective D2 dopamine receptor agonist. Psychopharmacology 113, 172-176.
5. Gugler R and von Unruh GE (1980) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 15, 367-383.
6. Haruta S, Iwasaki N, Ogawara K, Higaki K and Kimura T (1998) Absorption behavior of orally administered drugs in rats treated with propantheline. J Pharm Sci 87, 1081-1085.
7. Heinz N and Wolfgang L (1982) Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse. J Pharmacol Exp Ther 220, 654-659.
8. Hokama N, Hobara N, Kameya H, Ohshiro S and Sakanashi M (2007) Investigation of low levels of plasma valproic acid concentration following simultaneous administration of sodium valproate and rizatriptan benzoate. J Pharm Pharmacol 59, 383-386.
9. Ikeda H, Murakami T. Takano M, Usui T and Kihira K (2005) Pharmacokinetic interaction on valproic acid and recurrence of epileptic seizures during chemotherapy in an epileptic patient. Br J Clin Pharmacol 59, 593-597.
10. Klotz U and Antonin KH (1997) Pharmacokinetics and bioavailability of sodium valproate. Clin Pharmacol Ther 21, 736-743.
11. Legros B, Boon P, Dejonghe P, Sadzot B, Van Rijckevorsel K and Schmedding E (2007) Opinion of Belgian neurologists on antiepileptic drugs: Belgian study on epilepsy treatment (BESET). Acta Neurol Scand 115, 97-103.
12. Leviel V and Naquet R (1977) A study of the action of valproic acid on the kindling effect. Epilepsia 18, 229-234.
13. Moller JC and Oertel WH (2000) Pramipexole in the treatment of advanced Parkinson's disease. Eur J Neurol 7, 21-25.
14. Nimmo J, Heading RC, Tothill P and Prescott LF (1973) Pharmacological modification of gastric emptying: Effects of propantheline and metoclopromide on paracetamol absorption. Br Med J 10, 587-589.
15. Ohshiro S, Hobara N, Sakai M, Hokama N, Kameya H and Sakanashi M (2003) Effects of salicylate on the pharmacokinetics of valproic acid after oral administration of sodium valproate in rats. Biogenic Amines 17, 401-407.
16. Omoda K, Murakami T, Yumoto R, Nagai J, Maeda Y, Kiribayashi Y and Takano M (2005) Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenern antibiotics in rat and human. J Pharm Sci 94, 1685-1693.
17. Piercey MF, Hoffmann WE, Smith MW and Hyslop DK (1996) Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312, 35-44.
18. Schanker LS, Shore PA, Brodie BB and Hogben CA (1957) Absorption of drugs from the stomach in the rat. J Pharmacol Exp Ther 120, 528-539.
19. Simler S, Ciesielski L, Maitre M, Randrianarisoa H and Mandel P (1973) Effect of sodium n-dipropylacetate on andiogenic seizures and brain aminobutyric acid level. Biochem Pharmacol 22, 1701-1708.
20. Tamai I, Takanaga. H, Maeda H, Yabuuchi H, Sai Y, Suzuki Y and Tsuji A (1997) Intestinal brush-border membrane transport of monocarboxylic acids mediated by proton-coupled transport and anion transport mechanisms. J Pharm Pharmacol 49, 108-112.
21. Tsuji A, Takanaga H, Tamai I and Terasaki T (1994) Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm Res 11, 30-37.
22. Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters HS, Hutman LM, Glassman PM, Beck B, Paume D and Doyle C (2001) The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord 7, 115-120.
23. Wright CE, Sisson TL, Ichhpurani AK and Peters GR (1997) Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 37, 520-525.